Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
| العنوان: | Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer |
|---|---|
| المؤلفون: | Rajesh K. Thimmulappa, Vikas Misra, James G. Herman, Stephen Ames, David Sidransky, Mohammad O. Hoque, Anju Singh, Hannah Lee, Malcolm V. Brock, Stephen B. Baylin, Edward Gabrielson, Shyam Biswal |
| المصدر: | PLoS Medicine PLoS Medicine, Vol 3, Iss 10, p e420 (2006) |
| بيانات النشر: | Public Library of Science, 2006. |
| سنة النشر: | 2006 |
| مصطلحات موضوعية: | Lung Neoplasms, Somatic cell, Physiology, NF-E2-Related Factor 2, lcsh:Medicine, Antineoplastic Agents, Cancer: Lung, Biology, Adenocarcinoma, Genetics/Genomics/Gene Therapy, Loss of heterozygosity, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Gene expression, medicine, Genetics, Chemotherapy, Humans, Lung cancer, Gene, Transcription factor, 030304 developmental biology, Cancer Biology, 0303 health sciences, Kelch-Like ECH-Associated Protein 1, lcsh:R, Clinical Pharmacology, Intracellular Signaling Peptides and Proteins, General Medicine, Cell Biology, medicine.disease, Molecular biology, 3. Good health, Gene Expression Regulation, Neoplastic, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Cancer cell, Mutation, Cancer research, Carcinoma, Squamous Cell, Carcinoma, Large Cell, Efflux, Research Article |
| الوصف: | Background Nuclear factor erythroid-2 related factor 2 (NRF2) is a redox-sensitive transcription factor that positively regulates the expression of genes encoding antioxidants, xenobiotic detoxification enzymes, and drug efflux pumps, and confers cytoprotection against oxidative stress and xenobiotics in normal cells. Kelch-like ECH-associated protein 1 (KEAP1) negatively regulates NRF2 activity by targeting it to proteasomal degradation. Increased expression of cellular antioxidants and xenobiotic detoxification enzymes has been implicated in resistance of tumor cells against chemotherapeutic drugs. Methods and Findings Here we report a systematic analysis of the KEAP1 genomic locus in lung cancer patients and cell lines that revealed deletion, insertion, and missense mutations in functionally important domains of KEAP1 and a very high percentage of loss of heterozygosity at 19p13.2, suggesting that biallelic inactivation of KEAP1 in lung cancer is a common event. Sequencing of KEAP1 in 12 cell lines and 54 non-small-cell lung cancer (NSCLC) samples revealed somatic mutations in KEAP1 in a total of six cell lines and ten tumors at a frequency of 50% and 19%, respectively. All the mutations were within highly conserved amino acid residues located in the Kelch or intervening region domain of the KEAP1 protein, suggesting that these mutations would likely abolish KEAP1 repressor activity. Evaluation of loss of heterozygosity at 19p13.2 revealed allelic losses in 61% of the NSCLC cell lines and 41% of the tumor samples. Decreased KEAP1 activity in cancer cells induced greater nuclear accumulation of NRF2, causing enhanced transcriptional induction of antioxidants, xenobiotic metabolism enzymes, and drug efflux pumps. Conclusions This is the first study to our knowledge to demonstrate that biallelic inactivation of KEAP1 is a frequent genetic alteration in NSCLC. Loss of KEAP1 function leading to constitutive activation of NRF2-mediated gene expression in cancer suggests that tumor cells manipulate the NRF2 pathway for their survival against chemotherapeutic agents. Biallelic inactivation ofKEAP1, a frequent genetic alteration in NSCLC, is associated with activation of the NRF2 pathway which leads to expression of genes that contribute to resistance against chemotherapeutic drugs. Editors' Summary Background. Lung cancer is the most common cause of cancer-related death worldwide. More than 150,000 people in the US alone die every year from this disease, which can be split into two basic types—small cell lung cancer and non-small-cell lung cancer (NSCLC). Four out of five lung cancers are NSCLCs, but both types are mainly caused by smoking. Exposure to chemicals in smoke produces changes (or mutations) in the genetic material of the cells lining the lungs that cause the cells to grow uncontrollably and to move around the body. In more than half the people who develop NSCLC, the cancer has spread out of the lungs before it is diagnosed, and therefore can't be removed surgically. Stage IV NSCLC, as this is known, is usually treated with chemotherapy—toxic chemicals that kill the fast-growing cancer cells. However, only 2% of people with stage IV NSCLC are still alive two years after their diagnosis, mainly because their cancer cells become resistant to chemotherapy. They do this by making proteins that destroy cancer drugs (detoxification enzymes) or that pump them out of cells (efflux pumps) and by making antioxidants, chemicals that protect cells against the oxidative damage caused by many chemotherapy agents. Why Was This Study Done? To improve the outlook for patients with lung cancer, researchers need to discover exactly how cancer cells become resistant to chemotherapy drugs. Detoxification enzymes, efflux pumps, and antioxidants normally protect cells from environmental toxins and from oxidants produced by the chemical processes of life. Their production is regulated by nuclear factor erythroid-2 related factor 2 (NRF2). The activity of this transcription factor (a protein that controls the expression of other proteins) is controlled by the protein Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 holds NRF2 in the cytoplasm of the cell (the cytoplasm surrounds the cell's nucleus, where the genetic material is stored) when no oxidants are present and targets it for destruction. When oxidants are present, KEAP1 no longer interacts with NRF2, which moves into the nucleus and induces the expression of the proteins that protect the cell against oxidants and toxins. In this study, the researchers investigated whether changes in KEAP1 might underlie the drug resistance seen in lung cancer. What Did the Researchers Do and Find? The researchers looked carefully at the gene encoding KEAP1 in tissue taken from lung tumors and in several lung cancer cell lines—tumor cells that have been grown in a laboratory. They found mutations in parts of KEAP1 known to be important for its function in half the cell lines and a fifth of the tumor samples. They also found that about half of the samples had lost part of one copy of the KEAP1 gene—cells usually have two copies of each gene. Five of the six tumors with KEAP1 mutations had also lost one copy of KEAP1—geneticists call this biallelic inactivation. This means that these tumors should have no functional KEAP1. When the researchers checked this by staining the tumors for NRF2, they found that the tumor cells had more NRF2 than normal cells and that it accumulated in the nucleus. In addition, the tumor cells made more detoxification enzymes, efflux proteins, and antioxidants than normal cells. Finally, the researchers showed that lung cancer cells with KEAP1 mutations were more resistant to chemotherapy drugs than normal lung cells were. What Do These Findings Mean? These results indicate that biallelic inactivation of KEAP1 is a frequent genetic alteration in NSCLC and suggest that the loss of KEAP1 activity is one way that lung tumors can increase their NRF2 activity and develop resistance to chemotherapeutic drugs. More lung cancer samples need to be examined to confirm this result, and similar studies need to be done in other cancers to see whether loss of KEAP1 activity is a common mechanism by which tumors become resistant to chemotherapy. If such studies confirm that high NRF2 activity (either through mutation or by some other route) is often associated with a poor tumor response to chemotherapy, then the development of NRF2 inhibitors might help to improve treatment outcomes in patients with chemotherapy-resistant tumors. Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.0030420Test. US National Cancer Institute information on lung cancer and on cancer treatment MedlinePlus entries on small cell lung cancer and NSCLC Cancer Research UK information on lung cancer Wikipedia entries on lung cancer and chemotherapy (note that Wikipedia is a free online encyclopedia that anyone can edit) |
| اللغة: | English |
| تدمد: | 1549-1676 1549-1277 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::507ae2b78ffbc2c6a677d0a61cca80bbTest http://europepmc.org/articles/PMC1584412Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....507ae2b78ffbc2c6a677d0a61cca80bb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15491676 15491277 |
|---|